Akshi Kamboj (intern journalist) Drugs controller general of India (DCGI) gives approval to Pune-headquartered Brinton Pharmaceuticals for the sale of its antiviral drug Favipiravir under the brand name ‘Faviton’ for the treatment of covid-19 patients. the maximum retail price of the drug is decided to be Rs 59 per tablet.

Favipiravir is claimed to be an effective treatment against mild to moderate covid-19. The company will market the drug in India and export it to other countries as well.

“Our strategic intent will be to improve the access through our strong distribution network that will help make Faviton available across all COVID treatment centres and our MRP is Rs 59 per tablet.”

Brinton Pharma CMD Rahul Kumar Darda said.

About Post Author